Perceptions and attitudes of Egyptian health professionals and policy-makers towards pharmaceutical sales representatives and other promotional activities

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Kamal, Susan ^a   Holmberg, Christine ^b   Russell, Jean ^a   Bochenek, Tomasz ^c   Tobiasz Adamczyk, Beata ^c   Fischer, Christiane ^d   Tinnemann, Peter ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d MEZIS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; COMPUTER PROGRAM; DNA TRANSCRIPTION; DRUG INDUSTRY; EGYPT; EXPOSURE; GENETIC TRANSCRIPTION; HABIT; HEALTH CARE SYSTEM; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MARKETING; PERCEPTION; PHARMACIST; PHYSICIAN; PRESCRIPTION; SAMPLING; THEMATIC ANALYSIS; ADMINISTRATIVE PERSONNEL; ADULT; FEMALE; HEALTH PERSONNEL ATTITUDE; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; PSYCHOLOGY; QUALITATIVE RESEARCH;

ADMINISTRATIVE PERSONNEL; ADULT; ATTITUDE OF HEALTH PERSONNEL; DRUG INDUSTRY; EGYPT; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MARKETING; MIDDLE AGED; PHARMACISTS; PHYSICIANS; QUALITATIVE RESEARCH;

EID: 84949199243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140457     Document Type: Article

References (48)

1. Field MJ, Lo B. Conflict of interest in medical research, education, and practice. Washington, D.C: National Academies Press; 2009.
2. Rational use of medicines. Geneva, Switzerland: WHO [Online] Available: http://www.who.int/ medicines/areas/rational-use/en/. Accessed 30 March 2015.
3. De Freitas J, Haque OS, Bursztajn HJ, Cosgrove L, Gopal AA, Paul R, et al. The ethics of pharmaceutical industry influence in medicine. Geneva, Switzerland: UNESCO; 2013.
4. Clinical pharmacological evaluation in drug control. Geneva: WHO; 1993. Report on eighth European symposium. Bad Neuenahr 10-12 December 1992. EUR/ICP/DSE 173.
5. Brezis M, Wiist WH. Vulnerability of health to market forces. Med Care 2011; 49(3): 232. doi: 10.1097/ MLR.0b013e31820ab638 PMID: 21301368
6. CAPMAS, 2013. The Egyptian Population, 2013. Cairo: Central Agency for Public Mobilization and Statistics; 2013.
7. Nugent JB, Pesaran MH. Explaining growth in the Middle East. Vol. 278: Elsevier; 2007.
8. World Health Organization. The rational use of drugs: Report of the conference of experts, Nairobi. 25-29 November 1985: World Health Organization; 1987.
9. IMS Institute global use of medicines: outlook through 2016. Future Prescriber 2013; 14(1): 10-12.
10. World Health Organization. Paying for Health Services Fact sheet 2007.
11. American Chamber Business Studies Report. The Pharmaceutical Market in Egypt, 2006. Available: http://www.amcham.org.eg/resources-publications/publications/business-studies/PDF%20Files/ pharmasample.pdf. Cited on 24 April 2014.
12. Diaa M. Egypt Pharmaceutical Country Profile [Internet]. Cairo: Ministry of Health in collaboration with WHO; 2011 July. Available: http://www.who.int/medicines/areas/coordination/Egypt-PSCPNarrativeQuestionnaire-27112011.pdf. Cited on 2013 November 25.
13. Kandil A. The pharmaceutical industry and legislation in Egypt - historical perspectives and current practice. J Clin Pharm Ther. 1989; 14: 83-85. PMID: 2656730
14. Egyptian Drug Authority website. Available: http://www.eda.mohp.gov.eg/About/EDAWelcome.aspx? Main = about&aboutid=1&SubAbout=55. Cited on 24 April 2014.
15. Rubinstein RA. Breaking the bureaucracy: drug registration and neocolonial relations in Egypt. Soc Sci Med. 1998; 46: 1487-1494. PMID: 9665578
16. Burns N, Grove SK. Understanding nursing research: building an evidence-based practice. Missouri, United States: Elsevier Health Sciences; 2010.
17. Mack N, Woodsong C, MacQueen KM, Guest G, Namey E. Qualitative research methods: a data collectors field guide. 2005.
18. Marshall MN. Sampling for qualitative research. Fam Pract. 1996; 13: 522-525. PMID: 9023528
19. QSR NVIVO version 10.
20. Strauss A, Corbin J. Basics of qualitative research: procedures and techniques for developing grounded theory Thousand Oaks, CA: Sage; 1998.
21. Fortune 500 (2007). Top industries: most profitable industries, returns on investment. Available: http:// money.cnn.com/magazines/fortune/fortune500/2007/performers/industries/return-on-revenues/index. html. Cited on 31 March 2014.
22. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med. 2001; 110: 551-557. PMID: 11347622
23. Alssageer MA, Kowalski SR. A survey of pharmaceutical company representative interactions with doctors in Libya. Libyan Journal of Medicine. 2012; 7(1).
24. Ben Abdel Aziz A, Harrabi I, Rahmani S, Ghedira A, Gaha K, Ghannem H. [Attitudes of general practitioners to pharmaceutical sales representatives in Sousse]. Eastern Mediterranean Health Journal, 9 (5-6), 1075-1083, 2003. PMID: 16450540
25. Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in eastern Turkey. BMC Public Health. 2007; 7: 122. PMID: 17592644
26. Market Pulse, Available: http://www.stacommunications.com/journals/cpm/2009/04-April%2009/029-Prism.pdf. Cited on 28 January 2015.
27. Lieb K, Brandtonies S. A survey of German physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int. 2010; 107: 392-398. doi: 10.3238/arztebl.2010.0392 PMID: 20574555
28. Morelli G, Braganza A. Goal-setting barriers: a pharmaceutical sales force case study. The International Journal of Human Resource Management. 2012; 23: 312-332.
29. Oldani MJ. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthropol Q. 2004; 18: 325-356. PMID: 15484967
30. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS medicine. 2010; 7: e1000352. doi: 10.1371/journal.pmed.1000352 PMID: 20976098
31. Steinman MA, Bero LA, Chren M, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006; 145: 284-293. PMID: 16908919
32. Farthing-Papineau EC, Peak AS. Pharmacists' perceptions of the pharmaceutical industry. Am J Health Syst Pharm. 2005; 62: 2401-2409. PMID: 16278333
33. Mintzes B, Lexchin J, Sutherland JM, Beaulieu M, Wilkes MS, Durrieu G, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. Journal of General Internal Medicine. 2013; 28: 1368-1375. doi: 10. 1007/s11606-013-2411-7 PMID: 23558775
34. Alssageer MA, Kowalski SR. Doctors' opinions of information provided by Libyan pharmaceutical company representatives. The Libyan Journal of Medicine. 2012; 7.
35. Smith JL, Cervero RM, Valentine T. Impact of commercial support on continuing pharmacy education. J Contin Educ Health Prof. 2006; 26: 302-312. PMID: 17163494
36. Carney SL, Nair KR, Sales MA, Walsh J. Pharmaceutical industry-sponsored meetings: good value or just a free meal? Intern Med J. 2001; 31: 488-491. O'Keefe Daniel J. Persuasion: theory and research. Sage; 2002. PMID: 11720063
37. O'Keefe Daniel J. Persuasion: theory and research. Sage; 2002.
38. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. The American Journal of Bioethics. 2010; 10: 11-17. doi: 10.1080/ 15265161.2010.519226 PMID: 20945262
39. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ. 2003; 326: 1189-1192. PMID: 12775621
40. Groves K, Sketris I, Tett S. Prescription drug samples-does this marketing strategy counteract policies for quality use of medicines? J Clin Pharm Ther. 2003; 28: 259-271. PMID: 12911677
41. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Family Medicine Kansas city. 2002; 34: 729-731.
42. Pharmacy Law 127 for year 1955.
43. World Health Organization/Health Action International. Understanding and responding to pharmaceutical promotion: a practical guide. 1st ed. Geneva/Amsterdam: WHO/HAI; 2013.
44. Ashker S, Burkiewicz JS. Pharmacy residents' attitudes toward pharmaceutical industry promotion. Am J Health Syst Pharm. 2007; 64: 1724-1731. PMID: 17687062
45. Haines ST, Dumo P. Relationship between the pharmaceutical industry and pharmacy practitioners: undue influence? Am J Health Syst Pharm. 2002; 59: 1871-1874. PMID: 12374076
46. Schumock GT, Walton SM, Park HY, Nutescu EA, Blackburn JC, Finley JM, et al. Factors that influence prescribing decisions. Ann Pharmacother. 2004; 38: 557-562. PMID: 14966259
47. Mintzes B. Educational initiatives for medical and pharmacy students about drug promotion. An international cross-sectional survey. Geneva: World Health Organization (WHO/ PSM/ PAR/ 2005.2); 2005.
48. Zaki NM. Pharmacists' and physicians' perception and exposure to drug promotion: a Saudi study. Saudi Pharmaceutical Journal. 2014; 22: 528-536. doi: 10.1016/j.jsps.2014.02.008 PMID: 25561865